CLIMB BIO, INC. Deferred Costs, Current
CLIMB BIO, INC. (CLYM) had Deferred Costs, Current of $952.00 thousand as of 2024-03-31, per its 10-Q filed 2024-05-15.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredCostsCurrent · last filed 2024-05-15
- 2024-03-31: Deferred Costs, Current $952.00K.
- 2023-12-31: Deferred Costs, Current $0.00.
| Period end | Deferred Costs, Current |
|---|---|
| 2024-03-31 | $952.00K 10-Q · filed 2024-05-15 |
| 2023-12-31 | $0.00 10-Q · filed 2024-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |